FDA accepts BioCardia’s Helix catheter pre‑submission, review expected this quarter
BioCardia announced that the FDA has accepted its revised De Novo pre‑submission for the Helix transendocardial delivery catheter. The agency noted two possible clearance pathways and raised no safety concerns. The submission is supported by data from fifteen clinical trials involving nearly five hundred patients. BioCardia expects a substantive review with written feedback and a follow‑up meeting in the current quarter.
Why it matters
The FDA’s acceptance moves the Helix catheter toward potential marketing clearance, which could broaden BioCardia’s partnership opportunities with developers of cardiac cell, gene and protein therapeutics. The timing of the review will affect when the company can commercialize the device.
Key facts
- 1The FDA accepted BioCardia’s revised De Novo pre‑submission for the Helix catheter. stocktitan.net
- 2The agency indicated two pathways for marketing clearance and raised no safety concerns. stocktitan.net
- 3The submission includes clinical data from fifteen trials with nearly five hundred patients. stocktitan.net
- 4BioCardia expects a substantive FDA review with written feedback and a meeting this quarter (Q4 2026). stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.